DAVAMED™ C1 is a premium starch excipient designed specifically for direct compression in tablet manufacturing. It is a partially pregelatinized corn starch developed through advanced processing techniques to deliver superior functionality in pharmaceutical formulations and manufactured under strict GMP standards and compliant with major pharmacopeias such as USP/EP/ IP/ BP standards.
DAVAMED™ C1 boasts a unique combination of properties:It can be seamlessly substituted for more expensive microcrystalline cellulose (MCC), leading to significant cost savings without compromising quality. Additionally, DAVAMED™ C1 improves production by being perfectly suited for direct compression and hard capsule filling, eliminating the need for complex granulation processes.
But what truly sets DAVAMED™ C1 apart is its unwavering commitment to quality.
DAVAMED™ C1 is supported by a Drug Master File (DMF) filed with the U.S. Food and Drug Administration (USFDA), demonstrating full transparency and comprehensive documentation of our manufacturing process. In addition, it holds EXCiPACT certification—an internationally recognized standard verifying that our GMP and GDP systems meet the stringent requirements of pharmaceutical manufacturers.


Earning these certifications reflects our unwavering dedication to the highest quality standards. They enable our partners to confidently integrate DAVAMED™ C1 into their formulations, assured that it has undergone rigorous evaluation by leading regulatory authorities.
This comprehensive filing details every facet of DAVAMED™ C1's production, from the raw materials used to the rigorous quality control measures in place.
Key Benefits of DAVAMED™ C1
